Tokyo-Based Lion Changes Bufferin Distributor From BMS To Eisai
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Lion Corp, Bristol-Myers K.K and Eisai agreed May 12 to change the distributor of bufferin 81 mg and 330 mg tablets from BMKK to Eisai. Lion owns the manufacturing and marketing rights in Japan. Eisai has been actively promoting drugs that are combined with bufferin to treat cardiovascular disease. The distribution agreement will further strengthen Eisai's sales to medical facilities. Lion will continue to manufacture and sell the over-the-counter bufferin in Japan. (Click here for more - Japanese language